07.05.24 -- New Episodes Await! ADCs Ignited, mRNA Therapy for DMD, C&G Regulatory Guidance, and more.

Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA™ therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD.

Explore genetic regulation, synthetic biology's role in genetically programming mRNA to deliver therapies, and how Strand Therapeutics is enabling precise and controlled delivery with these mRNA constructs.

Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership deals, and a Daiichi Sankyo that can rightfully lay claim to lighting that fire.

If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-founded no fewer than 7 life sciences companies, and led investments at Pure Tech Ventures, the JDRF T1D Fund, SV Health investors, and now, the Dementia Discovery Fund, where he's a partner.

Asked about his company’s rapid rise since taking the helm in 2021, Arcellx CEO Rami Elghandour cites a few critical and risky decisions, the execution of some specific people on his all-star team, and a relentless commitment to diversity, equity, and inclusion. 

When we last caught up with Brian Culley, CEO of Lineage Cell Therapeutics, it was January 2021. On his long-overdue return to the Business of Biotech, Culley opens up on how the company addressed struggling programs, wrestled manufacturing control issues and delivery inefficiencies in its spinal cord program to the ground, and maintained control of its regulatory progress along the way.